Quantcast

Latest C-peptide Stories

2008-11-12 15:00:26

Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes.

2008-11-05 12:00:06

MONTREAL, Nov. 5 /PRNewswire-FirstCall/ -- ConjuChem Biotechnologies Inc. (TSX:CJB) announced today that dosing is complete for its Phase II clinical trial of PC-DAC(TM):Exendin-4.

2008-10-30 09:00:11

Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.

2008-09-23 09:00:15

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc.

2008-09-03 09:00:07

TEMPE, Ariz., Sept. 3, 2008 (GLOBE NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from a pre-clinical study of Chrysalin(r) (rusalatide acetate or TP508) in a model of chronic myocardial ischemia.

2008-08-07 12:01:26

Tolerx has started a pivotal Phase III clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes.

2008-08-06 12:00:58

JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com/), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801.

2008-08-06 09:01:04

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,407,940 by the United States Patent and Trademark Office, which includes the company's lead pre-clinical lipohexapeptide candidates.

2008-07-30 12:01:17

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

2008-07-15 12:01:01

-- GelVac(tm) Nasal Powder Platform Delivers Peptide Arginine-Vasopressin (AVP) Into Systemic Circulation -- Peptide Widely Used to Control Urine Output in Patients With Diabetes Insipidus -- Additional Commercial Opportunities Could Include a Treatment for Heart Failure -- Formulation Stable at Room Temperature For More Than 18 Months IRVING, Texas, July 15, 2008 (PRIME NEWSWIRE) -- DelSite, Inc.


Word of the Day
lahar
  • A volcanic mudflow.
The word 'lahar' comes from Javanese.
Related